An IL-2 Receptor Targeted Toxin with Reduced VLS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI063910-01
Agency Tracking Number: AI063910
Amount: $144,786.00
Phase: Phase I
Program: SBIR
Awards Year: 2005
Solitcitation Year: 2005
Solitcitation Topic Code: N/A
Solitcitation Number: PHS2005-2
Small Business Information
ANJIN GROUP, INC.
10 Chilhowie Ct., Cockeysville, MD, 21030
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JOHANNA VANDERSPEK
 (410) 561-1434
 ANJIN_GROUP@EARTHLINK.NET
Business Contact
Phone: (508) 831-6383
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Well over a decade ago the first diphtheria toxin-based fusion protein toxin, DAB389IL-2 (Ontak(R)) was in development as the first of a new class of receptor specific therapeutic agent. This fusion protein gained FDA approval five years ago for the treatment of refractory cutaneous T cell lymphoma. The fusion protein toxin technology has not been widely developed due adverse events, especially vascular leak syndrome (VLS), associated with administration of these agents. The Anjin Group Inc [AGI] proposes to develop a third generation diphtheria toxin-based platform, modified to reduce VLS. Fusion protein toxins developed from such a toxophore may have broader clinical application due to an altered risk benefit profile for patients including those with non-life threatening disease.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government